Else Nutrition Announces Major Breakthrough: President Trump Signs Pivotal FDA Funding Package that Includes Congressional Directive Streamlining Regulatory Pathway for Non-Dairy, Non-Soy Plant-Based Infant Formula

Executive Summary

• U.S. Federal Budget for FY 2026, signed by President Donald Trump, includes language directing the FDA to create streamlined approval pathways for non‑dairy, non‑soy plant‑based infant formulas.
• The directive is expected to accelerate regulatory review and market entry for Else Nutrition’s plant‑based infant formula products in the United States.
• Else Nutrition plans to intensify engagement with the FDA and federal representatives to capitalize on the new regulatory environment.

Key Details

• Legislative Action: FY 2026 budget (H. Rept. 119‑172) contains a congressional directive that requires the FDA to establish clear approval pathways and formal guidance for plant‑based, non‑soy, non‑dairy infant formulas.
• Impact on Company: The company expects the FDA’s streamlined process to begin promptly now that the government shutdown has ended, enabling faster U.S. market access for its products.
• Company Positioning: Else Nutrition will accelerate direct engagement with the FDA and federal officials to ensure implementation of the new guidance aligns with its product standards and timelines.
• Product Pipeline: Existing toddler nutrition line (almonds, buckwheat, tapioca) is already commercialized; the regulatory change positions the company to launch its plant‑based infant formula in the U.S. market once FDA pathways are defined.
• Strategic Significance: The directive represents a major business milestone, potentially expanding the addressable market for Else Nutrition and enhancing nutritional equity for infants with dairy or soy sensitivities or families seeking plant‑based options.

Notable Quotes

“For too many parents, the absence of truly inclusive formula options has been a daily worry,” said Hamutal Yitzhak, Co‑Founder & CEO.
“Congress has sent a clear directive: U.S. regulatory policy will soon catch up to the reality that babies' nutritional needs and families' values are evolving.”

Materiality Assessment: Material – Positive (the regulatory change directly affects the company’s ability to bring core products to a major market, representing a significant positive catalyst).